

Medical Drug Clinical Criteria

Subject: Nexobrid (anacaulase-bcdb)

Document #: CC-0260

Status: New

Publish Date: 04/01/2024

Last Review Date: 11/17/2023

Table of Contents

[Overview](#)

[Coding](#)

[References](#)

[Clinical Criteria](#)

[Document History](#)

Overview

This document addresses the use of Nexobrid (anacaulase-bcdb). Nexobrid contains proteolytic enzymes and is FDA approved for eschar removal in adults with deep partial thickness and/or full thickness thermal burns. Nexobrid is administered by a healthcare professional in up to two applications 4 hours apart. Up to 20% BSA (40 grams of Nexobrid) can be treated across two treatment sessions.

Escharotomies are procedures done in partial or full thickness thermal burns to relieve eschar tightness, assess extent of wounds and need for grafts. Eschar removal can be done surgically, with enzymatic debridement or allowing the natural process of debridement to occur. Nexobrid is an enzymatic form of eschar removal.

Clinical Criteria

Nexobrid (anacaulase-bcdb)

Requests for Nexobrid (anacaulase-bcdb) may be approved if the following criteria are met:

- I. Individual is using for eschar removal of deep partial thickness and/or full thickness thermal burns

Requests for Nexobrid (anacaulase-bcdb) may not be approved for the following:

- I. Individual with chemical or electrical burns; **OR**
- II. Individual is treating burns to the face, perineum, or genitalia; **OR**
- III. Individual is treating burns on the feet and is also diagnosed with diabetes mellitus or an occlusive vascular disease; **OR**
- IV. Individual is treating circumferential burns; **OR**
- V. Individual has significant cardiopulmonary disease, including inhalation injury.

Quantity Limits

Quantity Limits

Drug	Limit
Nexobrid (anacaulase-bcdb) for topical gel	440 grams per 2 days

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

ICD-10-PCS

XW00X27

Introduction of Bromelain-enriched Proteolytic Enzyme into Skin, External Approach, New Technology Group 7

XW01X27 Introduction of Bromelain-enriched Proteolytic Enzyme into Subcutaneous Tissue, External Approach, New Technology Group 7

HCPCS

J7353 Anacaulase-bcdb, 8.8% gel, 1 gram

ICD-10-CM

T300-T3199 Total Body Surface Burn of third degree burns
T21120XA-T21139A Burns on Truck, Second degree initial encounter
T22200A-T22399A Shoulder and Upper Limb Second degree burns initial encounter
T23201A- T23399A Wrist and Hand burn of Second degree initial encounter
T24201A- T24399A Lower Limb burn of second degree initial encounter
T25211A-T25399A Ankle and foot burn of second degree initial encounter

Document History

New: 04/01/2024

Document History:

- 04/01/2024 – Select Review: Add new clinical document for Nexobrid (anacaulase-bcdb). Coding Reviewed: Added ICD-10-PCS XW00X27- XW01X27. Added HCPCS J7353. Added ICD-10-CM T300-T3199, T21120XA-T21139A, T22200A-T22399A, T23201A- T23399A, T24201A- T24399A, T25211A-T25399A.

References

1. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
2. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
3. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc. Updated periodically.
4. A Study to Evaluate the Efficacy and Safety of Nexobrid in Subjects With Thermal Burns. ClinicalTrials.gov identifier: NCT02148705. Updated February 19, 2019. Accessed February 21, 2023. <https://clinicaltrials.gov/ct2/show/study/NCT02148705>

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association